Summary of clinical results

DUCRAY
KELUAL DS - Crème réparatrice

Clinical study of the safety and efficacy of KELUAL DS soothing cream in subjects with seborrheic dermatitis.

Dermatologically controlled clinical study of the safety and efficacy of KELUAL DS Soothing Face Cream on teenagers and adults with mild to moderate seborrheic dermatitis of the face.

Population

60 subjects included

30% women/70% men (13 - 64 years) with mild to moderate seborrheic dermatitis of the face

  • Erythema ≥ 1
  • Pruritus ≥ 1
  • Desquamation ≥ 1

Application of KELUAL DS Soothing Face Cream

1 single application per day in the attack phase, then twice a week in the maintenance phase

Evaluation criteria

  • Clinical score by investigator: desquamation, erythema (scale from 0 to 4)
  • Scoring by subject: average pruritus (analog scale from 0 to 10)
  • Samples + qualitative metagenomic analysis by Haut sequencing of fungal and bacterial populations including Malassezia globosa, Malassezia restricta, Staphylococcus epidermidis, Staphylococcus aureus and Cutibacterium acnes

Results

Highly significant reduction in clinical signs after 7 days of treatment: desquamation, pruritus and erythema. 

Intra-group analysis, **: p<0.001

Evolution of the clinical desquamation score 

during 15 days of treatment and during a 6-week maintenance phase

Image 1
  • Average pruritus: -62% after 7 days of treatment
  • Erythema: -35% after 7 days' treatment

After 15 days of treatment, the majority Malassezia population is reduced in favor of new fungal families: Penicillium, Cladosporium and Debaryomyces. 

 

Evolution of the fungal microbiome after 15 days of treatment

Kelual DS crème apaisante résultats

Good skin tolerance

Conclusion

After 15 days of treatment with KELUAL DS Soothing Cream, improvement in clinical symptoms correlates with rebalancing of the fungal microbiome. The increase in microbiome biodiversity thus approximates that of a healthy scalp.

More summaries of clinical results